secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001193125-25-303115
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 2.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio sells complement inhibitor ADX-097 to Akebia for up to $592M total consideration
--------------------------------------------------------------------------------

- Upfront and guaranteed near-term payments of $12M ($7M at closing, $3M at 6 months, $2M milestone).
- Eligible for up to $92.5M in development/regulatory milestones and $487.5M commercial milestones.
- Tiered royalties on future sales of ADX-097 from low single-digit to mid-teen percent.
- Cash runway extended into H2 2027; topline SIGNAL-AA Part B data expected mid-2026.
- Q32 retains tissue-targeted complement platform including ADX-096; evaluating strategic options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312525303115/0001193125-25-303115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312525303115/d70163d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-303115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer